Clinical proof-of-concept has been demonstrated in a small Phase 2a trial where 4 weeks of treatment with an RORγt inhibitor VTP-43742 showed efficacy in patients with moderate to severe plaque psoriasis, accompanied by the reduction of IL-17A and IL-17F up to 75% in patient serum63. Here, IL17A is linked to psoriasis vulgaris.